TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences

Reuters10-08

TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences

TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573092844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573092844","market":"us","top_or_hot":-1,"title":"TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> acquires Polynoma and secures 25 million investment from CK Life Sciences\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAZ","symbol_name":"TransCode Therapeutics  Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL7rMKPn:1","article_id":"2573092844","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573092844","pubTimestamp":1759924947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.Disclaimer: This news brief was created by Public Technologies  using generative ar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNAZ":"TransCode Therapeutics  Inc.","BK4539":"次新股","BK1161":"生物科技","BK1569":"长和系","00775":"长江生命科技","BK4139":"生物科技"},"translate_title":"TransCode Therapeutics收购Polynoma获长江生命科技2500万投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00775":0.9,"RNAZ":0.9},"content_text":"TransCode Therapeutics acquires Polynoma and secures 25 million investment from CK Life Sciences\n    \n\n        TransCode Therapeutics has acquired 100% of the issued and outstanding interests of Polynoma from CK Life Sciences, expanding its oncology pipeline. As part of the transaction, CK Life Sciences is making a $25 million strategic equity investment in TransCode. The acquisition brings Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma, into TransCode's portfolio alongside its microRNA-based candidate, TTX-MC138, which targets microRNA-10b in metastatic cancer. Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while remaining Chairman of the Board. Tom Fitzgerald will continue as Chief Financial Officer, and Elizabeth Czerepak, MBA, joins as an independent board member and Chairperson of the Audit Committee. The integration of Polynoma's team is expected to strengthen TransCode's clinical and development capabilities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE93003) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573092844","isCrawlerRequest":true}